Early interim PET scan in Hodgkin lymphoma: Where do we stand?

Andrea Gallamini; Martin Hutchings; Abraham Avigdor; Aaron Polliack

doi:10.1080/10428190801888704

Early interim PET scan in Hodgkin lymphoma: Where do we stand?

Andrea Gallamini^*, Martin Hutchings, Abraham Avigdor, Aaron Polliack

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Positron emission tomography using [18F]-fluoro-2-deoxy-D-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.

Original language	English
Pages (from-to)	659-662
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	49
Issue number	4
DOIs	https://doi.org/10.1080/10428190801888704
State	Published - Apr 2008
Externally published	Yes

Keywords

ABVD
BEACOPP
Interim
Lymphoma
PET
Prognosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428190801888704

Cite this

@article{612fd87737eb4cf8b4c7eb3976d4e4b4,

title = "Early interim PET scan in Hodgkin lymphoma: Where do we stand?",

abstract = "Positron emission tomography using [18F]-fluoro-2-deoxy-D-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.",

keywords = "ABVD, BEACOPP, Interim, Lymphoma, PET, Prognosis",

author = "Andrea Gallamini and Martin Hutchings and Abraham Avigdor and Aaron Polliack",

year = "2008",

month = apr,

doi = "10.1080/10428190801888704",

language = "אנגלית",

volume = "49",

pages = "659--662",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - Early interim PET scan in Hodgkin lymphoma

T2 - Where do we stand?

AU - Gallamini, Andrea

AU - Hutchings, Martin

AU - Avigdor, Abraham

AU - Polliack, Aaron

PY - 2008/4

Y1 - 2008/4

N2 - Positron emission tomography using [18F]-fluoro-2-deoxy-D-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.

AB - Positron emission tomography using [18F]-fluoro-2-deoxy-D-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.

KW - ABVD

KW - BEACOPP

KW - Interim

KW - Lymphoma

KW - PET

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=42049087919&partnerID=8YFLogxK

U2 - 10.1080/10428190801888704

DO - 10.1080/10428190801888704

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 18398732

AN - SCOPUS:42049087919

SN - 1042-8194

VL - 49

SP - 659

EP - 662

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 4

ER -

Early interim PET scan in Hodgkin lymphoma: Where do we stand?

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this